Drug Type Small molecule drug |
Synonyms Quinidine gluconate (USP), Duraquin, Quinact + [3] |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers), α-adrenergic receptor antagonists(Alpha adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (12 Jul 1950), |
Regulation- |
Molecular FormulaC26H36N2O9 |
InChIKeyXHKUDCCTVQUHJQ-LCYSNFERSA-N |
CAS Registry7054-25-3 |
Start Date26 Aug 2024 |
Sponsor / Collaborator |
Start Date06 Oct 2022 |
Sponsor / Collaborator |
Start Date01 Oct 2022 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00642 | Quinidine Gluconate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Discovery | US | 01 Oct 2011 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | (kztcluriuy) = qlzwbcuazl jbwwlfbisl (reqtvzvnjb ) View more | - | 07 Apr 2024 | |||
Not Applicable | - | rczchusrth(mpdinhgdgz): HR = 0.74 (95% CI, 0.22 - 2.48), P-Value = 0.62 | - | 03 Sep 2019 | |||
Phase 1 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | tujrysxejs(zfjxenozmc) = jjorgpiofw kcucabxdwt (fkrqrvaoup, wfgbakxxtm - lqfrhrvhdn) View more | - | 26 Oct 2018 | ||
mhbgwnvjpx(rcadyrgclh) = exifahahct pisyvyfpiz (fckulkqgsn, zrkorqpocj - oagjtyckzj) View more | |||||||
Not Applicable | Epilepsy KCNT1 mutation | 6 | hjgzavvlaw(zepeszpzol) = mluysbwwet jsscinvlpn (vmbvwwguwy, -0.25 to 4.25) | Negative | 04 Sep 2017 | ||
hjgzavvlaw(zepeszpzol) = huunfrlxsu jsscinvlpn (vmbvwwguwy, -0.25 to 4.25) | |||||||
Not Applicable | - | - | nxqqdngqmx(jlazgncjci) = afgoljkpyj ndlqnboiyz (tqrkjzzmbq, ± 12.4) | - | 12 Jun 2002 |